Gilead Sciences has completed its acquisition of MiroBio for $405 million. As a result of the acquisition, Gilead received the proprietary MiroBio research platform and the entire portfolio of immuno-inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is now in Phase 1 clinical trials.